Treatment Considerations in Early Breast Cancer MEDSTAT_JS MEDSTAT_CSS

Treatment Considerations in Early Breast Cancer

In this video roundtable, Dr Kevin Kalinsky is joined by Dr Aditya Bardia, Dr Ruth O'Regan, and Dr Yara Abdou for a discussion on recent treatment advances in early breast cancer. The panel reviews genomic assays and considerations for choosing appropriate therapy for individual patients.

Video 1: Genomic Assays and Other Markers

The panelists discuss genomic assays, including Oncotype DX and RSClin, as well as patient scenarios in which each assay should be used in clinical practice. Data supporting the use of circulating tumor DNA and its clinical application are also reviewed.

Up Next

Video 1: Genomic Assays and Other Markers
Video 2: Optimizing Endocrine Therapy
Video 3: Triple-Negative Breast Cancer

About the Panel

Kevin Kalinsky, MD Photo

Kevin Kalinsky, MD

  • Assistant Professor of Medicine
  • Winship Cancer Institute
  • Emory University
  • Atlanta, Georgia
Yara Abdou, MD Photo

Yara Abdou, MD

  • Assistant Professor
  • Department of Medical Oncology
  • University of North Carolina at Chapel Hill
  • Chapel Hill, North Carolina
Aditya Bardia, MD, MPH Photo

Aditya Bardia, MD, MPH

  • Associate Professor
  • Department of Medical Oncology
  • Harvard Medical School
  • Director, Breast Cancer Research
  • Massachusetts General Hospital
  • Boston, Massachusetts
Ruth O'Regan, MD Photo

Ruth O'Regan, MD

  • Charles A. Dewey Professor
  • Chair of Medicine
  • University of Rochester School of Medicine and Dentistry
  • Physician-in-Chief
  • Department of Medicine
  • Strong Memorial Hospital
  • Rochester, New York
Disclosures

Kevin Kalinsky, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer; Eli Lilly and Company; Novartis
Holds stock in: Grail; Array Biopharma; Pfizer

Yara Abdou, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Exact Sciences

Aditya Bardia, MD, MPH, has disclosed the following relevant financial relationships:
Received research grant from: Genentech; Novartis; Pfizer; Merck; Sanofi; Radius Health; Immunomedics
Received income in an amount equal to or greater than $250 from: Pfizer; Novartis; Genentech; Merck; Radius Health; Immunomedics/Gilead; Sanofi; Daiichi Pharma/AstraZeneca

Ruth O'Regan, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer; Genomic Health; Biotheranostics; Novartis; Eli Lilly and Company; PUMA; Genentech; Immunomedics; Macrogenics
Received research grant from: Novartis
Received income in an amount equal to or greater than $250 from: Pfizer; Genomic Health; Biotheranostics; Novartis; Eli Lilly and Company; PUMA; Genentech; Immunomedics; Macrogenics